Filed Aug. 26, 2026

Serial No. 50072913

Examining Attorney null

Class Pharmaceutical preparations for the prevention and treatment of migraine, chronic migraine, episodic migraine, and migraine-associated disorders; biologics for the prevention and treatment of migraine; biopharmaceutical preparations for the prevention and treatment of migraine and migraine-associated disorders; biological preparations for therapeutic use in the prevention and treatment of migraine; bispecific antibodies for therapeutic use, namely for the prevention of migraine; pharmaceutical preparations comprising anti-PACAP antibodies for the prevention and treatment of migraine; pharmaceutical preparations comprising anti-CGRP antibodies for the prevention and treatment of migraine; pharmaceutical preparations comprising bispecific antibodies targeting both CGRP and PACAP for therapeutic use in the prevention of migraine; pharmaceutical preparations for the treatment of neurological disorders; biologic preparations for the treatment of neurological disorders; pharmaceutical preparations for subcutaneous injection for the prevention of migraine; injectable pharmaceutical preparations in the field of migraine prevention; pharmaceutical preparations for self-administration via autoinjector for the prevention of migraine; pharmaceutical preparations for quarterly subcutaneous administration for the prevention of migraine; monospecific antibodies for therapeutic use, namely for the prevention of migraine; 005; 006; 018; 044; 046; 051; 052

Case Type Trademark